BMS Psoriasis Drug Demonstrates Efficacy in Late-Stage Trial

Bristol Myers Squibb (BMS) has released positive results from a phase 3 trial evaluating deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, as a treatment for moderate-to-severe plaque psoriasis.

The drug met both primary endpoints vs. placebo, demonstrating a 75 percent improvement in the condition and achieving a disease status of clear or almost clear following 16 weeks of treatment.

The company previously announced results from a separate phase 3 study in November 2020 that affirmed the drug’s effectiveness.